Release no. 3, 2011

Copenhagen and Oslo, 18th March 2011, 2011-03-18 11:02 CET (GLOBE NEWSWIRE) --Affitech A/S (NASDAQ OMX: AFFI) announced today that one of the Company's
Norwegian investors Ferd AS have received 3.281.375 shares in Affitech due to
the fact that the investment fund Teknoinvest VII KS has been dissolved. Ferd
AS was a limited partner (investor) in Teknoinvest VII KS. Ferd AS total
holding after this transaction is 39.296.847 shares equal to 8,06% of the total
outstanding shares. Ferd AS is represented in Affitechs Board of Directors by
Pål Rødseth.


About Affitech

Affitech AS is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic
antibody company based in Copenhagen, Denmark with R&D facilities in Oslo,
Norway. The company utilizes a range of proprietary antibody technologies for
the discovery of fully human antibodies for application in oncology,
inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is
Affitech's premier discovery engine for the isolation of lead antibodies to
cell surface molecules in situ. Several of the Company's proprietary product
candidates were generated by CBAS™. Further information is available at
www.affitech.com.

For more information please contact

Randi Krogsgaard, Director IR & Communications

Tel # +45 2320 1001, e-mail: [email protected]